Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
1521.HK
Strong BuyFrontage Holdings Corporation · Healthcare · United States · $310M · Avg Vol: $42K/d
93
StockRankGet insider-trade alerts
Q
53
V
68
M
73
P/E (TTM)
38.8x
ROE
2.0%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
FINANCIAL SUMMARY (HKD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.0B | 2.0B | 2.0B | 2.0B | 0.8% | 2.0B | 2.2B | 2.4B | 10.3% |
| EPS (HKD) | 0.10 | 0.04 | 0.00 | 0.03 | -35.4% | 0.03 | — | — | — |
| Shares | 2.1B | 2.0B | 2.0B | 2.0B | -1.4% | 2.0B | — | — | — |
| Debt | 926.5M | 1.1B | 1.2B | 1.0B | 2.6% | 1.0B | — | — | — |
| Equity | 2.6B | 2.7B | 2.6B | 2.7B | 1.4% | — | — | — | — |
| Op CF | 489.5M | 311.5M | 318.6M | 344.3M | -11.1% | 344.3M | — | — | — |
| Inv CF | -1.2B | -686.9M | -325.2M | -108.5M | — | — | — | — | — |
| Fin CF | 240.3M | 101.2M | -80.1M | -292.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+11.1%
SMA 50SMA 200
Close
$0.1531
RSI (14)
32.8
52W High
$0.2028
From 52W High
0.8%
SCORE BREAKDOWN
Quality
53
ROIC
4.4%56.4
ROE
2.0%50.1
GP/Assets
12.8%32.5
Op. Margin
6.8%58.3
FCF/Assets
6.0%73.4
Piotroski
497.6
Int. Cover
2.5x45.9
D/E Ratio
0.37x37.1
Current Ratio
1.33x21.2
Value
68
P/E (TTM)
38.8x27.6
EV/EBITDA
7.7x81.1
P/FCF
9.6x84.4
P/B
0.1x100.0
P/S
1.2x80.5
Div Yield
—N/A
Momentum
73
52W High %
75%57.9
RS 6M
13%75.3
SMA 50/200
1.08x75.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
326%95.2
FUNDAMENTALS
Market Cap
$310M
P/E (Forward)
15.2x
Gross Margin
27.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1521.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 1521.HK | Frontage Holdings Corporation(you) | $310M | 93 | Strong Buy |
| AGEN | Agenus Inc. | $345M | 84 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $194M | 97 | Strong Buy |
| QTTB | Q32 Bio Inc. | $487M | 88 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $471M | 99 | Strong Buy |
| ORMP | Oramed Pharmaceuticals Inc. | $200M | 82 | Strong Buy |
| CRMD | CorMedix Inc. | $645M | 98 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $692M | 87 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $843M | 99 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
Peer medians: ROE -25.8% · P/E 29.5x · Gross margin 58.8%